173 related articles for article (PubMed ID: 11066455)
1. Acute promyelocytic leukemia (AML-M3)--Part 1: Pathophysiology, clinical diagnosis, and differentiation therapy.
Randolph TR
Clin Lab Sci; 2000; 13(2):98-105. PubMed ID: 11066455
[TBL] [Abstract][Full Text] [Related]
2. Acute promyelocytic leukemia (AML-M3)--Part 2: Molecular defect, DNA diagnosis, and proposed models of leukemogenesis and differentiation therapy.
Randolph TR
Clin Lab Sci; 2000; 13(2):106-16. PubMed ID: 11066449
[TBL] [Abstract][Full Text] [Related]
3. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
4. Acute promyelocytic leukemia: recent advances in diagnosis and management.
Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid as a single agent induces complete remission in a patient with acute leukemia of M2a subtype.
Chen Z; Wang Y; Wang W; Gong J; Xue Y
Chin Med J (Engl); 2002 Jan; 115(1):58-61. PubMed ID: 11930660
[TBL] [Abstract][Full Text] [Related]
6. Retinoid receptor expression and its correlation to retinoid sensitivity in non-M3 acute myeloid leukemia blast cells.
Lehmann S; Paul C; Törmä H
Clin Cancer Res; 2001 Feb; 7(2):367-73. PubMed ID: 11234892
[TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors.
Avvisati G; Lo Coco F; Mandelli F
Semin Hematol; 2001 Jan; 38(1):4-12. PubMed ID: 11172535
[TBL] [Abstract][Full Text] [Related]
8. Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia.
Raza S; Ullah K; Ahmed P; Khan B
J Coll Physicians Surg Pak; 2008 Sep; 18(9):546-50. PubMed ID: 18803891
[TBL] [Abstract][Full Text] [Related]
9. Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia.
Tallman MS
Leukemia; 1996 Apr; 10 Suppl 1():S12-5. PubMed ID: 8618462
[TBL] [Abstract][Full Text] [Related]
10. beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid.
Wu JJ; Cantor A; Moscinski LC
Leuk Res; 2007 Jan; 31(1):49-57. PubMed ID: 16764927
[TBL] [Abstract][Full Text] [Related]
11. Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application.
Wang Z; Sun G; Shen Z; Chen S; Chen Z
Chin Med J (Engl); 1999 Nov; 112(11):963-7. PubMed ID: 11721474
[TBL] [Abstract][Full Text] [Related]
12. Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma.
Masetti R; Biagi C; Zama D; Vendemini F; Martoni A; Morello W; Gasperini P; Pession A
Adv Ther; 2012 Sep; 29(9):747-62. PubMed ID: 22941525
[TBL] [Abstract][Full Text] [Related]
13. Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease.
Sirulnik LA; Stone RM
Clin Adv Hematol Oncol; 2005 May; 3(5):391-7, 429. PubMed ID: 16167012
[TBL] [Abstract][Full Text] [Related]
14. A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all-trans retinoic acid) therapy.
Naeem M; Harrison K; Barton K; Nand S; Alkan S
Eur J Haematol; 2006 Feb; 76(2):164-6. PubMed ID: 16405439
[TBL] [Abstract][Full Text] [Related]
15. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
Tsai DE; Luger SM; Andreadis C; Vogl DT; Kemner A; Potuzak M; Goradia A; Loren AW; Perl AE; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Thompson JE; Swider C; Bagg A; Mato AR; Carroll M
Clin Cancer Res; 2008 Sep; 14(17):5619-25. PubMed ID: 18765556
[TBL] [Abstract][Full Text] [Related]
17. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
Niitsu N; Ishii Y; Matsuda A; Honma Y
Cancer Res; 2001 Jan; 61(1):178-85. PubMed ID: 11196157
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based therapy for leukemia: a lesson from ATRA therapy.
Naoe T
Nagoya J Med Sci; 2001 Nov; 64(3-4):103-8. PubMed ID: 11820331
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of the AML-XH-99-M3 protocol for treatment of acute promyelocytic leukemia in children].
Chen J; Gu LJ; Tang JY; Xue HL; Pan C; Ye QD; Jiang H; Dong L; Zhou M; Wang YP
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):329-32. PubMed ID: 18554461
[TBL] [Abstract][Full Text] [Related]
20. [Recent progress in the treatment of acute leukemia].
Kimura Y
Gan To Kagaku Ryoho; 2003 Jul; 30(7):895-901. PubMed ID: 12894700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
